SpyGlass Pharma grants 105K stock options to insider

SpyGlass Pharma, Inc. director and officer Malik Y. Kahook received a grant of stock options covering 105,000 shares of common stock on February 5, 2026 at an exercise price of $16 per share.

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. director and officer Malik Y. Kahook received a grant of stock options covering 105,000 shares of common stock on February 5, 2026 at an exercise price of $16 per share. These options are held as direct beneficial ownership.

The options vest over time: 25% of the shares vest on the one-year anniversary of the February 5, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years. The options expire on February 5, 2036, and this grant brings his total derivative holdings from this award to 105,000 options.

Insider Trade Summary

Grant/Award: 105,000 shares

Grant/Award 1 txn

Insider Kahook Malik Y.

Role See remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	105,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 105,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

FAQ

What insider transaction did SpyGlass Pharma (SGP) report for Malik Y. Kahook?

SpyGlass Pharma reported a grant of stock options to Malik Y. Kahook. He received 105,000 options to buy common shares at $16 per share, classified as a direct, derivative security award under the company’s equity incentive arrangements.

How many SpyGlass Pharma (SGP) stock options were granted in this Form 4 filing?

The filing reports a grant of 105,000 stock options. These options give the right to purchase SpyGlass Pharma common stock at a fixed $16 exercise price, representing a significant equity-based compensation award to the reporting person.

What is the exercise price and expiration date of the SpyGlass Pharma (SGP) options?

The stock options have an exercise price of $16 per share and expire on February 5, 2036. This means the holder can buy SpyGlass Pharma common shares at $16 any time during the option term, once vested and subject to plan conditions.

What is the vesting schedule for Malik Y. Kahook’s SpyGlass Pharma (SGP) option grant?

The vesting schedule is time-based and service-dependent. Twenty-five percent of the 105,000 options vest on the one-year anniversary of February 5, 2026, with one-forty-eighth of the total vesting monthly thereafter, assuming continued service to SpyGlass Pharma.

What roles does Malik Y. Kahook hold at SpyGlass Pharma (SGP) in this filing?

The filing identifies Malik Y. Kahook as both a director and an officer of SpyGlass Pharma. The remarks section specifies his titles as President, Chief Medical Officer, and Executive Chair, indicating multiple key leadership responsibilities at the company.

Is the SpyGlass Pharma (SGP) option grant reported as direct or indirect ownership?

The option grant is reported as direct ownership. The Form 4 classifies the 105,000 stock options as directly held derivative securities, without any noted intermediary entity or indirect ownership structure in the ownership or footnote disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kahook Malik Y.

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		105,000		(1)	02/05/2036	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

Remarks:

President, Chief Medical Officer, Executive Chair

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.